Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,125 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza Virus Vaccine Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

H9 Priming Study in Healthy Adults

NCT00617331
View directory record Official record
Conditions
Influenza
Interventions
Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

NCT06361875
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5421, Quadrivalent Influenza mRNA Vaccine MRT5424, Quadrivalent Influenza mRNA Vaccine MRT5429, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine, Quadrivalent Recombinant Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
11
States / cities
San Diego, California • Hialeah, Florida • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

NCT01068912
View directory record Official record
Conditions
Influenza
Interventions
Favipiravir, Placebo comparator
Drug
Lead sponsor
MDVI, LLC
Industry
Eligibility
20 Years to 80 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
148
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 17, 2026, 2:14 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Investigating the Effectiveness of a Seasonal Influenza Vaccination Promotion Campaign for Members of a Non-Profit, Community-Based Health Insurance Plan: 2018-2019

NCT03700281
View directory record Official record
Conditions
Influenza, Vaccination
Interventions
Messaging, Incentive
Behavioral
Lead sponsor
The University of Texas Health Science Center at Tyler
Other
Eligibility
18 Years and older
Enrollment
22,584 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

NCT00952419
View directory record Official record
Conditions
Influenza, Swine-origin A/H1N1 Influenza
Interventions
Monovalent Subvirion A/H1N1 Influenza vaccine, Normal saline solution (placebo)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 9 Years
Enrollment
474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
20
States / cities
Miami Beach, Florida • Marietta, Georgia • Woodstock, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

NCT01657929
View directory record Official record
Conditions
Influenza A Subtype H5N1 Infection
Interventions
H5-VLP + GLA-AF, H5-VLP alone, H5-VLP + Alhydrogel(R), Licensed H5N1 vaccine
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 49 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

Alternative Oseltamivir Dosing Strategies

NCT00334529
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

NCT01353729
View directory record Official record
Conditions
Influenza, Human
Interventions
600 mg zanamivir + moxifloxacin placebo, 1200 mg zanamivir + moxifloxacin placebo, zanamivir placebo + moxifloxacin placebo, zanamivir placebo + 400 mg moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)

NCT01773928
View directory record Official record
Conditions
Influenza
Interventions
Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified), VCIV manufactured with the current manufacturing process (VCIV current), Fluzone®, licensed trivalent influenza vaccine (TIV)
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,928 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
20
States / cities
Chandler, Arizona • Anaheim, California • Paramount, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

NCT02915302
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
1,950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Harrisburg, Arkansas • Downey, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 17, 2026, 2:14 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety Study of FluMist With and Without Ampligen

NCT01591473
View directory record Official record
Conditions
Influenza, Human
Interventions
Poly I:Poly C12U 50 ug, Poly I:Poly C12U 200 ug, Poly I:Poly C12U 500 ug, Poly I:Poly C12U 1250 ug, Placebo, FluMist
Drug
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
19 Years to 49 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

REDucing Influenza Among University Students, University of California at Berkeley

NCT00448773
View directory record Official record
Conditions
Influenza-like Illness, Influenza
Interventions
Online education
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
17 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Pomegranate Products for Prevention of Common Cold

NCT00617318
View directory record Official record
Conditions
Influenza, Common Cold, Cough, Headache, Fever
Interventions
Pomegranate, Placebo
Dietary Supplement
Lead sponsor
Texas Heart Institute
Other
Eligibility
21 Years to 49 Years
Enrollment
461 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2008 · Synced Oct 17, 2026, 2:14 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

NCT03381196
View directory record Official record
Conditions
Influenza A
Interventions
Pimodivir 600 mg, Placebo, SOC Treatment
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
13 Years to 85 Years
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsboro, Alabama • California City, California + 105 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

NCT00912496
View directory record Official record
Conditions
Influenza
Interventions
MF-59, A/Anhui/05, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
637 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Not applicable Interventional Results available

Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department

NCT02957136
View directory record Official record
Conditions
Respiratory Tract Infections, Influenza, Human, Common Cold
Interventions
Rapid respiratory pathogen nucleic acid amplification test
Device
Lead sponsor
University of California, Davis
Other
Eligibility
1 Year to 101 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults

NCT00380211
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine (A/H3N2, A/H1N1, and B strains), Fluarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
6
States / cities
Miami, Florida • Lenexa, Kansas • Binghamton, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 17, 2026, 2:14 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

NCT06435936
View directory record Official record
Conditions
PHA1A
Interventions
Single Ascending Dose of SAB-176, Single Ascending Dose of Placebo
Drug
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People

NCT06683352
View directory record Official record
Conditions
Influenza,Human, COVID-19
Interventions
Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Placebo
Biological · Combination Product · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
22
States / cities
Lake Forest, California • San Diego, California • Walnut Creek, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Immunization Delivery in Obstetrics and Gynecology Settings

NCT01565135
View directory record Official record
Conditions
Immunization Status Among Obstetrics and Gynecology Patients
Interventions
Multimodal Vaccine Program
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years and older · Female only
Enrollment
97,087 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Jet Injection for Influenza

NCT01688921
View directory record Official record
Conditions
Influenza, Human
Interventions
AFLURIA vaccine (2012-2013 formulation), Needle-Syringe, Stratis needle-free injection device
Biological · Device
Lead sponsor
PharmaJet, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Fort Collins, Colorado • Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

NCT05422326
View directory record Official record
Conditions
Influenza, Human, Influenza in Birds, Respiratory Tract Infections, Infections, Orthomyxoviridae Infections, RNA Virus Infections, Virus Diseases, Respiratory Tract Diseases
Interventions
aH5N6c on Day 1, aH5N6c on Day 22, Placebo on Day 22
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
18
States / cities
Huntsville, Alabama • Tempe, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population

NCT00377585
View directory record Official record
Conditions
Influenza
Interventions
Fluarix, adjuvanted influenza vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
3,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
10
States / cities
Clearwater, Florida • Coral Gables, Florida • Milford, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 17, 2026, 2:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Influence of Chronic CMV Infection on Influenza Vaccine Responses

NCT02134184
View directory record Official record
Conditions
Cytomegalovirus Infections, Influenza
Interventions
Fluzone® 2012-2013 Formula NDC No 498281-012-50
Biological
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 17, 2026, 2:14 AM EDT